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PTGS2, and TGF‑β1 overexpression 
on immunomodulatory properties 
of hTERT‑MSCs and their 
extracellular vesicles
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Hamid Reza Bidkhori5, Thorsten R. Doeppner6,8 & Ahmad Reza Bahrami1,7,8*
The therapeutic potential of mesenchymal stem cells (MSCs) is out of the question. Yet, recent 
drawbacks have resulted in a strategic shift towards the application of MSC‑derived cell‑free products 
such as extracellular vesicles (EVs). Recent reports revealed that functional properties of MSCs, 
including EV secretion patterns, correlate with microenvironmental cues. These findings highlight the 
urgent need for defining the optimal circumstances for EV preparation. Considering the limitations 
of primary cells, we employed immortalized cells as an alternative source to prepare therapeutically 
sufficient EV numbers. Herein, the effects of different conditional environments are explored on 
human TERT‑immortalized MSCs (hTERT‑MSCs). The latter were transduced to overexpress IDO1, 
PTGS2, and TGF-β1 transgenes either alone or in combination, and their immunomodulatory 
properties were analyzed thereafter. Likewise, EVs derived from these various MSCs were extensively 
characterized. hTERT‑MSCs‑IDO1 exerted superior inhibitory effects on lymphocytes, significantly 
more than hTERT‑MSCs‑IFN‑γ. As such, IDO1 overexpression promoted the immunomodulatory 
properties of such enriched EVs. Considering the limitations of cell therapy like tumor formation and 
possible immune responses in the host, the results presented herein might be considered as a feasible 
model for the induction of immunomodulation in off‑the‑shelf and cell‑free therapeutics, especially for 
autoimmune diseases.
Mesenchymal stem cells (MSCs) have been widely applied in cell-based regenerative  medicine1,2. Besides their 
conventional attribution to regeneration, it is now also evident that MSCs are naturally involved in maintaining 
immune  homeostasis3. Immunosuppressive and immune-privileged properties have been reported for these 
 cells4, which made them a promising target for exploring their possible therapeutic applications in T-cell-medi-
ated  diseases5,6. Despite profound  outcomes7, there are still some controversies in their applications. While MSCs 
are assessed as safe and efficient based on a vast number of previous pre-clinical and clinical studies, their clinical 
application is yet limited by the risk of genomic and chromosomal instability acquired during culture, as well 
as in vivo tumorigenesis and altered functional properties. Moreover, heterogeneity is considered as one of the 
most important disadvantages of these  cells8,9.
Immunosuppressive features of MSCs are mainly attributed to their secretion  products10,11. Among these, 
indoleamine 2,3-dioxygenase-1 (IDO-1), prostaglandin-E2 (PGE2), nitric oxide (NO), transforming growth 
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factor (TGF)-β1, hepatocyte growth factor (HGF), and interleukin (IL)- 10 have been top listed as the most 
efficient  ones12–20. IDO (IDO1) is the rate-limiting enzyme in the tryptophan catabolic  pathway21 and is regarded 
as one of the key modulators of acquired immune  tolerance22. Its immunomodulatory role has been reported in 
several different studies, particularly during  pregnancy23, chronic  infection24, autoimmune  diseases25, drug resist-
ance in  cancer26,27, and following  transplantation23. In addition to other experiments, these observations made a 
meaningful shift from cell-based therapies to strategies like managing an immunological  microenvironment28–30. 
This could be obtained by applying active components of the stem cells’ supernatant, mainly their extracellular 
vesicles (EVs)29,31–33. The EVs have recently been realized as important mediators of intercellular communication 
 processes34–37. Hence, EVs are now proposed as exciting means in cell-free therapeutics due to their remarkable 
properties, including enhanced distribution patterns, higher stability, and lower side-effects38. Furthermore, it 
is also advisable to manipulate parental cells of EVs to provide a tool for cargo transport of enriched desirable 
 agents39,40. It seems that EVs are proper candidates to overcome the concerns regarding the therapeutic appli-
cation of engineered cells. EVs from regular or engineered MSCs are recognized as practical delivery tools in 
therapeutic  programs41, even though the consequences of these modifications are still under  investigation42.
Nevertheless, enhancing the therapeutic efficiency of MSC-derived EVs is currently under investigation 
 worldwide43. The utilization of pre-conditioning, genetic engineering, and culture condition modifications could 
be considered as effective approaches during in vitro expansion of the  cells44,45. MSCs are prominently in the focus 
of the exosome-related studies due to their competence for producing remarkable amounts of exosomes. This 
capacity is not limited to bone marrow MSCs and was also indicated for adipose-derived cells (Ad-MSCs)46–48.
In the present study, we first investigated the potential of using immortalized hTERT-MSCs as a proper 
substitute for primary cells to overcome the problems associated with heterogeneity of the cells, as well as other 
limitations such as low proliferation capacity and cellular senescence observed during culture of primary mes-
enchymal stem cells.
Thereafter, we studied secretion patterns of MSCs with regard to EV production. Finally, the cells were fur-
ther exposed to various treatments or engineered with candidate transgenes to investigate optimal conditions 
for obtaining a qualified subtype of immunoregulatory MSCs and their corresponding EVs. Thus, the notion 
here would be empowering the immunomodulatory properties of hTERT-MSCs and their EV counterparts to 
be introduced as a platform for the management of acute inflammatory status. Induction of allograft tolerance 
following organ transplantation, reducing the application of immunosuppressive drugs to prevent unfavorable 
side effects, and solving the endurable and long-lasting problems of patients with autoimmune diseases could 
be considered as an important perspective of such biological stem cell products.
Results
Flow cytometric analysis confirmed desirable immunophenotype of different cell 
types. hTERT-MSCs were characterized for the expression of different molecular markers. As demonstrated 
in Fig. 1a, these cells follow the same standard expression pattern which is typical of MSCs. As indicated by flow 
cytometry analysis, around 35% of  CD45+ Jurkat cells were also positive for the CD3 marker. About 90% of these 
 CD3+ cells were concurrently positive for CD4 expression (Fig. 1b). Human PBMCs were mostly composed of 
 CD45+/CD3+ (72.9%) lymphocytes (Fig. 1c–e).
The activated anti‑inflammatory state of hTERT‑MSCs was induced through conditioning or 
genetic modification strategies. IFN‑γ induces IDO1 expression in hTERT‑MSCs. The chemical treat-
ment with IFN-γ had no adverse effects on the viability of hTERT-MSCs at both 250 U/ml and 500 U/ml concen-
trations after 72 h, as demonstrated by the MTT assay. We treated the cells with 20 µg/ml poly(I:C), resulting in 
a decrease in cell viability during the first 24 h, followed by regaining their normal growth rate (Supplementary 
Fig. S1A). Immunocytochemistry experiments revealed that IFN-γ remarkably induced IDO1 and PTGS2 ex-
pressions in the hTERT-MSCs at 72 h post-treatment at the protein level. However, modification in the expres-
sion level of the TGF-β1 protein was not considerable in comparison to the untreated cells (Supplementary 
Fig. S1B). In the case of cells treated with poly(I:C) (20 µg/ml) for 72 h, minor IDO1 expression was detected 
by fluorescence microscopy at protein level (data not shown). As demonstrated in Supplementary Fig.  S1C, 
Western blot analysis revealed that the main target proteins, IDO1, PTGS2, and TGF-β1 are expressed differen-
tially following treatment with IFN-γ and poly(I:C), in comparison to the untreated cells. Of note, a remarkable 
increase in protein levels of IDO1 and PTGS2, was evident for the IFN-γ treated cells.
hTERT‑MSCs express target transgenes. HEK293T cells were transfected with the candidate plasmids to over-
express our target genes, including IDO1, PTGS2, and TGF‑β1 (Supplementary Fig. S2). These genes were short 
listed based on the results from conditioning experiments and extensive literature review, confirming their func-
tional integrity with immunomodulatory properties of MSCs. Concentrated viral suspensions were applied for 
infecting the hTERT-MSCs (Fig.  2a–e). As demonstrated (Fig.  2f), in all cases, more than 95 percent of the 
genetically manipulated cells were positive for GFP expression following 2 days of puromycin selection, con-
firming that the cells received desirable lentiviral particles in all cases. To confirm the overexpression of target 
genes following viral transduction, qRT-PCR experiments were performed.
Microscopic observations indicated that treatment of the cells with IFN-γ (250 U/ml) and poly(I:C) (20 µg/
ml) and even their manipulation with the IDO1, PTGS2, and TGF‑β1 genes did not change the normal mor-
phology of the cells (Fig. 3a–e, top panel). To investigate the effects of various modalities on the differentiation 
potential of hTERT-MSCs towards mesodermal lineages, we cultured these cells in osteogenic induction medium. 
As shown in Fig. 3 (a–f, bottom panel), treatment of the hTERT-MSCs with 20 µg/ml poly(I:C), but not IFN-γ, led 
to a considerable increase in osteogenic differentiation. The osteogenic differentiation capacity of the cells was 
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not negatively affected by the transgenes in comparison to the cells transduced with the normal GFP express-
ing vector. As revealed by our flow cytometric analysis, hTERT-MSCs bearing lentiviral constructs retain their 
mesenchymal origin, as was confirmed by the expression of CD44 and CD73 by more than 95% and 94% of the 
cells, respectively (Supplementary Fig. S3).
hTERT‑MSCs release desirable amounts of EVs into their conditioned media. The capacity of 
the hTERT-MSCs for efficient production of EVs was investigated via nanoparticle tracking analysis in addi-
tion to the BCA assay. As demonstrated in Supplementary Fig. S4, a remarkable number of EVs with proper 
size (40–150 nm) and protein concentration are produced by these cells. These EVs were positive for expressing 
common exosomal markers, including CD63 and TSG101, as approved by Western blot experiments (Supple-
mentary Fig. S4C).
Figure 1.  Flow cytometric characterization of different cells. (a) hTERT-MSCs: hTERT-MSCs were positive for 
CD44 and CD73, but they were negative for CD45, CD11b, HLA-DR and CD19 markers. (b) Jurkat cells: Most 
(99.2%) of the Jurkat cells express the hematopoietic cell marker CD45, and 34.9% of the total cell population 
are  CD3+. About 90% of these  CD3+ cells are also positive for CD4 expression. (c–e) Human PBMCs: About 
9% of the cells were positive for CD45 and about 73% of the cells were  CD45+CD3+. Monocytes and platelets 
were mostly removed by centrifugation steps before analysis. PI staining was applied to remove dead cells 
from analysis. Data were obtained by BD Accuri C6 and analyzed using FlowJo Software (version 7.6, Becton, 
Dickinson and Company; 2019).
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Based on characterization data, all EV preparations indicated proper integrity (Fig. 4 top and bottom panels), 
Figure 2.  Transduction of hTERT-MSCs with target genes. Fluorescence microscopy analysis of modified 
hTERT-MSCs (a–e) represents transduction with GFP, IDO1, PTGS2, and TGF-β1 target genes in addition 
to transduction with combinatorial viral particles (co-transduced group), respectively (Nikon, Japan, scale 
bars represent 100 pixel). (f) Efficiency assessment of gene transfer into hTERT-MSCs for GFP, IDO1, PTGS2, 
TGF-β1 or co-transduced cells as evident by flow cytometric detection of green fluorescent protein (Data were 
obtained by BD Accuri C6 and analyzed using FlowJo Software version 7.6).
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size distribution (Supplementary Fig. S4E, F), and polydispersity index (mean PDI 0.2–0.3) in addition to accept-
able levels of Zeta potential with proper mobilities (Supplementary Table S1). A heterogeneous surface, obviously 
detectable for most EV populations in atomic force microscopic images, was an indicator for the presence of pro-
teins in the lipid membrane of the vesicles (Fig. 4 top panel). The mean EV diameter as measured for 10 particles 
in each case was equal to 249.81 ± 29.98 (hTERT-MSCs-GFP), 330.72 ± 19.24 (-IDO1), 229 ± 14.58 (-PTGS2), 
302.72 ± 19.13 (TGF-β1), and 353.27 ± 11.41 (co-transduced cells) for investigated groups. These particle sizes 
were in accordance with the ones obtained based on Z-average in particle size analytical experiments. Results 
of non-contact mode force spectroscopy demonstrated that hTERT-MSCs-IDO1-EVs have the highest level of 
adhesion/rupture forces (Supplementary Fig. S5).
Figure 3.  Top; Morphological analysis of hTERT-MSCs. Untreated cells (a), hTERT-MSCs-IFN-γ (250 U/ml) 
(b), hTERT-MSCs-poly(I:C) (20 µg/ml) (c), hTERT-MSCs-GFP (d), and hTERT-MSCs-co-transduced with 
IDO1, PTGS2 and TGF‑β1 viral particles (e) upon reaching confluency (light microscope, Olympus, Japan, scale 
bars represent 500 µm). Bottom; Osteogenic differentiation of hTERT-MSCs. Untreated/unprimed hTERT-
MSCs (a) or primed with differentiation inductive medium (b) were considered as controls. Cells primed in 
the permanent presence of IFN-γ (250 U/ml) (c), or poly(I:C) (20 µg/ml) (d), and following transduction with 
control GFP (e) or co-transduction with IDO1, PTGS2 and TGF‑β1 viral particles (f) are shown. Alizarin red 
S staining is applied for detection of calcification after 21 days of induction (fluorescent microscope, Olympus, 
Japan, scale bars represent 200 µm).
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Figure 4.  Top; Atomic force microscopy. (a–c) represent amplitude images obtained for untreated cells, hTERT-
MSCs-IFN-γ (250 U/ml), and hTERT-MSCs-poly(I:C) (20 µg/ml) in scan size range of 3 µm. (d–g) represent 
amplitude images obtained for (hTERT-MSCs)-GFP, -IDO1, -PTGS2 and -TGF-β1, respectively. Three different 
scan size ranges including 3, 5 and 10 µm were applied for the AFM studies. Image processing and analysis 
were performed by Imager version 1.00 AraResearch Co. Bottom; Electron micrographs from three hTERT-
MSCs-GFP derived EV samples (a–c) using transmission electron microscopy (Leo 912ab, Zeiss, Germany, 
120 kV, Tungsten filament, holy carbon film grid). As demonstrated the vesicle-like particles of different sizes 
(50–200 nm) as well as lipid bilayer membranes of intact spherical EVs are prominent. (d–f) Transmission 
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Gene expression analysis revealed a differential pattern of expression for a set of innate 
and adaptive immune‑related molecular markers. Gene expression profiles of hTERT-MSCs were 
explored following conditioning of the cells with different concentrations of human recombinant IFN-γ and 
poly(I:C) at various time points (Supplementary Fig. S6A–C). Quantitative RT-PCR experiments revealed that 
IDO1 expression is significantly induced with both concentrations of IFN-γ at all the investigated time points, 
although the highest level of induction was observed for 250 U/ml IFN-γ at 48 h post-treatment. In addition, 
treating the cells with poly(I:C) (20 µg/ml) led to a minor but significant overexpression of IDO1 at 48 h (Sup-
plementary Fig. S6B). Likewise, expression of PTGS2, TGF‑β1, and TDO2 followed the same pattern at this time 
point. As indicated in Supplementary Fig. S6B, a considerable overexpression of the examined genes except for 
IDO2 happened 48 h post-treatment. IDO2, on the contrary, was downregulated 24 h and 48 h (Supplementary 
Fig. S6A,B) after treatment but was upregulated in cells treated for 72 h (Supplementary Fig. S6C). Besides, 
gene expression experiments were performed on the same samples to investigate the expression levels of a set of 
other genes encountered with immune-related function. As demonstrated in Fig. 5, treating the hTERT-MSCs 
with both IFN-γ and poly(I:C) resulted in significant upregulation of DDX‑58, IFIH1, OAS2, and STING genes 
(Fig. 5a). Moreover, the IFN-γ treatment led to a significant induction in PD‑L1, and TLR‑4 expression. The 
transgenic hTERT-MSCs were also applied for gene expression analysis to determine their gene expression pro-
files (Fig. 5b). These molecular studies revealed that in accordance to the cells treated with IFN-γ or poly(I:C), 
the expression of MYD88, STING, DDX‑58, IFIH1, and PD‑L1 was significantly induced in hTERT-MSCs-co-
transduced cells. While in hTERT-MSCs transduced with each of the transgenes individually, we did not observe 
any statistically significant modifications in the expression levels of these genes.
hTERT‑MSCs and their cell‑free products are immunosuppressive. hTERT‑MSCs exert immuno‑
suppressive features under different circumstances. The functional analysis using lymphocyte inhibition assay 
(colorimetric assay, Orangu dye) revealed that the hTERT-MSCs inhibited the proliferation of human PBMCs 
by 17% following treatment with 250 U/ml IFN-γ. This was more efficient following the transduction of the 
cells with viral particles carrying the gene constructs of IDO1, PTGS2, or TGF‑β1 genes, as the mean inhibition 
rates were scored as 31%, 30%, and 38%, respectively (Supplementary Table S2). However, the hTERT-MSCs co-
transduced with all three viral particles showed the highest level of lymphocyte proliferation inhibition (more 
than 60%) (Fig. 6a, red columns). As demonstrated, hTERT-MSCs-IFN-γ also exert significant inhibitory effects 
against Jurkat cells (50%), while similar effects against Jurkat cells were only observed for IDO1 and PTGS2 
transduced cells, though to a lesser extent (Fig. 6a, blue columns). Regarding the conditioned medium of the 
cells applied for functional analysis, no inhibitory effects were observed against Jurkat cells (Fig. 6a, green col‑
umns). However, anti-proliferative effects of virally transduced cells against human PBMCs were evident when 
compared to GFP transduced cells. These inhibitory effects were more prominent (~ 20%) in the case of IDO1 
transduced cells (Fig. 6a, yellow columns).
Inhibitory effects of IFN-γ treated hTERT-MSCs against Jurkat cells were also confirmed during flow cytomet-
ric CFSE analysis for PHA stimulated cells (the default number of peaks: 8). Inhibitory effects of IFN-γ treated 
cells led to a remarkable decrease of divided cells (%), from 17 to 10.6% on day 3 and 41.3 to 3.1% on day 5, for 
primed cells in comparison to untreated cells, respectively (Fig. 7). Moreover, proliferation and division indices 
of 4.84 and 0.63 were respectively obtained for PBMCs cultured with IFN-γ-primed cells compared to untreated 
cells (5.28 and 2.18) on day 5. Similar immunosuppressive effects were also confirmed for IFN-γ treated cells 
(Precursor frequency or %Divided: 10.9%) in comparison to untreated cells (%Divided: 24.9%) via flow cyto-
metric approach on day 2 of co-culture experiments with hPBMCs (Fig. 8a,b). CFSE labeling also confirmed 
the improved immunosuppressive features of all virally transduced cells in comparison to GFP transduced cells. 
Percent divided (%Divided), division index (Div. Index), proliferation index (Prol. Index) and Peak CVs obtained 
for different treatments following 2 days of co-culture experiments were as follows respectively: hTERT-MSCs-
GFP (18.4%, 0.42, 2.31, 8.43), hTERT-MSCs-IDO1 (2.98%, 0.06, 2.23, 5.81), hTERT-MSCs-PTGS2 (14.8%, 0.25, 
1.73, 6.35), hTERT-MSCs-TGF-β1 (16.8%, 0.41, 2.44, 12.1) and hTERT-MSCs-co-transduced (5.15%, 0.13, 2.52, 
9.99) (Fig. 8c–g). These data from colorimetric and flow cytometric analyses indicated the superiority of IDO1 
transduced cells compared to other virally transduced cells for in vitro induction of lymphocyte inhibition. 
EVs from primed/genetically modified hTERT‑MSCs exert in vitro immunosuppressive properties. As inhibitory 
effects were revealed for all transduced cells, the possibility of mimicking these effects by their extracellular 
counterparts, emphasizing on EVs was also explored. Likewise their parent cells, regardless of the modification 
target, EVs from transduced cells exhibited the most inhibitory effects in comparison to EVs from uncondi-
tioned, or IFN-γ- and poly(I:C)-primed hTERT-MSCs (Supplementary Table S3). Analysis of the colorimetric 
Orangu assay revealed 70% inhibition of the human PBMCs proliferation when exposed with EVs derived from 
the aforementioned transduced cells (IDO1, PTGS2, and TGF‑β1) compared to the PBMCs in the absence of any 
EVs (Fig. 6b, Exosomes, 96 h co‑culture). However, this rate difference was just significant in the case of IDO1 
EVs against hTERT-MSCs-GFP EVs after 96 h (p < 0/0001). It means that despite the superior immunomodula-
tory properties of GFP transduced cells in comparison to untreated or primed cells, the expression of IDO1 in 
EV producer cells enhanced the immunomodulatory properties of their descendent EVs by 13.54%, which is a 
considerable amount (Supplementary Fig. S7). This is achieved by considering the mean viability of the PBMCs 
in the presence of hTERT-MSCs-GFP EVs equal to 100%. Then, the mean inhibitory effects for IDO1 EVs will 
be equal to 86.49%.
Our data reveals that the second least inhibitory effect of the exosomes on PBMC proliferation belongs to 
those extracted from the cells which were transduced with GFP constructs. This inhibition is in line with some 
previous reports which postulated that GFP protein expression can cause T-cell mediated immunogenicity 
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Figure 5.  Gene expression analysis. (a) Gene expression analysis (mean of independent experiments ± SEM) 
for hTERT-MSCs following treatment with IFN-γ (250 U/ml, 48 h), poly(I:C) (20 µg/ml, 48 h) and BiP (10 µg/
ml, 72 h) in comparison to untreated cells using qRT-PCR analysis. (b) Gene expression analysis (mean of 
independent experiments ± SEM) of the hTERT-MSCs bearing different gene constructs in comparison to GFP 
transduced cells via qRT-PCR analysis. Among different candidate immune encountered genes, genes depicting 
statistically significant differences (significance level p < 0.05) after modification in comparison to untreated 
cells/GFP transduced cells are demonstrated. Data analysis was performed by CFX Manager Software (version 
1.6) and GraphPad Prism, version 6.00. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
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and  apoptosis49. Meanwhile such base line effect is apparently neutralized in treatments with exosomes of the 
PTGS2 and TGF‑β1 constructs rather than IDO1 for unknown reasons. One could argue that they may load 
less GFP protein into the exosomes or cover its functional negative effects. This remains as an open question to 
Figure 6.  Lymphocyte inhibition assay. (a) Lymphocyte inhibition assay was performed following three 
days of co-culture experiments between PBMCs or Jurkat cells and hTERT-MSCs transduced with different 
viral particles or treated with interferon gamma (250 U/ml) or poly(I:C) (20 µg/ml). As demonstrated, some 
experiments were performed for 4-day conditioned media of the cells. Relative ODs (450 nm) in each group 
were read following 4 h incubation of Orangu dye with hPBMCs by an ELISA reader (Awareness Technology, 
USA). Data are represented as mean of viabilities ± SEM. (b) Functional analysis of cell-free products from the 
hTERT-MSCs. Lymphocyte inhibition assay experiments were performed for exosomes, PEG-concentrated 
ultracentrifuge supernatants and ultracentrifuge supernatants without any modification in the permanent 
presence of 3 µg/ml PHA as proliferation stimulant. 72 h and 96 h co-cultures were applied for functional 
analysis based on the detection of viable cells via sensitive Orangu dye. All experiments were performed against 
human PBMCs except for the ultracentrifuge supernatant which was performed against Jurkat cells. During 
all co-culture experiments we applied the hPBMCs/Jurkat cells to MSCs ratio as 10:1. For cell-free products 
100 µg of the products were added to the culture media of hPBMCs/Jurkat cells  (106 cells/well). Data represent 
mean of three independent experiments. Relative ODs (450 nm) in each group were read by an ELISA reader 
(Awareness Technology, USA) following 4 h incubation.
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be investigated with further experiments. This however does not change the fact that IDO1 carrying exosomes 
exert the highest level of PBMC inhibition.
Inhibitory effects of the ultracentrifuge-supernatants as negative controls were also explored against Jurkat 
cells during our experiments. Although some significant inhibitory effects were observed for the ultracentrifuge-
supernatants obtained from the cells transduced with IDO1 (21%) and co-transduced (11%) cells after 72 h, such 
effects were demolished in the medium after 96 h in the presence of PHA (Fig. 6b).
Inhibitory effects of EVs from modified hTERT-MSCs against allogenic human PBMCs were also confirmed 
via flow cytometric approach. As revealed by the CFSE cell inhibition assay, peak ratios and proliferation indices 
were decreased for EVs from virally transduced or IFN-γ primed cells in comparison to EVs from hTERT-MSCs-
GFP. Proliferation indices for different treatments were recorded as GFP-EVs (2.68), IDO1-EVs (2.31), PTGS2-
EVs (1.47), TGF-β1-EVs (2.28), and co-trans-EVs (2.62). It was accompanied by a higher number of the parent 
cells left undivided in the presence of EVs from IDO1, TGF‑β1, and IFN-γ groups.
Discussion
Characteristics such as easy accessibility, multi-lineage differentiation capacity, immunoregulatory features, 
directed tissue homing, and less ethical concerns have led to an extensive application of MSCs in regenerative 
medicine. Nevertheless, translational results to apply MSCs in clinical settings are still  insufficient50. The reason 
of the latter lies in heterogeneous phenotypes of MSCs and high clearance rates of grafted MSCs within injured 
organs and  tissues51. Interestingly, the biological functions of MSCs depend on their surrounding microenviron-
ment, yielding defined paracrine effects for which EVs play a significant  role52. MSCs have a remarkable capac-
ity for transferring their mitochondria and efficient release of  exosomes53–58. EVs are crucial for intercellular 
communication processes between immune-competent and non-competent  cells59, 60, and modifying immune 
responses within the host  organ52,61–63. Although the precise molecular mechanisms by which MSC-derived 
EVs regulate the immune responses are still unknown, evidence suggests that MSCs are able to transfer various 
cargos such as miRNA and others by EVs.
Figure 7.  Lymphocyte inhibition assay (CFSE analysis). Results from flow cytometric analysis of the inhibitory 
effects of hTERT-MSCs against Jurkat cells following 3 to 5 days of co-culture experiments. (a,d) untreated 
hTERT-MSCs, (b,e) IFN-γ (250 U/ml)-primed and (c,f) poly(I:C) (20 µg/ml)-primed cells after 72 h and 120 h 
of culture, respectively. 3 µg/ml of PHA was applied as cell proliferation stimulant for Jurkat cells. IFN-γ priming 
of the cells resulted in lower percentage of divided cells and decreased amounts of division index in both 
investigated time periods in comparison to untreated cells (Jurkat cells: MSCs ratio 10:1). Data were obtained by 
BD Accuri C6 and analyzed using FlowJo Software (version 7.6).
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Figure 8.  Lymphocyte inhibition assay (CFSE analysis). Results from flow cytometric analysis of the inhibitory 
effects of hTERT-MSCs against human PBMCs following 2 days of co-culture experiments. CFSE-labelled 
human PBMCs cultured (a) in the absence of any cells or in the presence of (b) hTERT-MSCs-IFN-γ (250 U/
ml), (c) hTERT-MSCs-GFP, (d) hTERT-MSCs-IDO1, (e) hTERT-MSCs-PTGS2, (f) hTERT-MSCs-TGF-β1 and 
(g) hTERT-MSCs-co-transduced. As shown hTERT-MSCs-IDO1 demonstrated the highest level of lymphocyte 
inhibition followed by hTERT-MSCs-co-transduced (PBMCs: MSCs ratio 10:1). Data were obtained by BD 
Accuri C6 and analyzed using FlowJo Software (version 7.6).
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As the biological properties of MSCs depend on their cellular microenvironment, the characteristics of 
EVs also depend on their parental  cells64. Hence, various pre-conditioning techniques or modification of MSC 
expression profiles have recently been regarded to enrich EVs with desirable  features65–69. The present study 
strived first to improve the immunomodulatory capacity of MSCs and their EV derivatives thereafter. As such, 
the experimental paradigm included priming of hTERT-MSCs with various agents or the ectopic expression of 
different genes in these cells as described in the materials and methods. EV enrichment was performed from 
these different host cells. The treated cells or their derivatives from both experiments were subjected to functional 
analysis to evaluate their immunoregulatory properties.
Herein, we used hTERT-MSCs as a model cell line due to the prominent immunoregulatory properties of 
adipose-derived MSCs compared to other sources of  MSCs70–74. Furthermore, these cells have a normal karyo-
type and differentiation capacity and do not show any tumorigenic effects in vivo75. In line with this, hTERT-
immortalization was previously proposed as a feasible way of producing cell lines with an amenable ability for 
producing therapeutic  EVs76–78.
For the first time, a report by Krampera attributed IFN-γ priming of bone marrow-derived MSCs to the 
enhancement of immunomodulatory proteins, mainly  IDO179. Similar observations were also described for 
poly(I:C), a well-known analog of  dsRNA80–82, and BiP/Glucose-Regulated Protein 78 (GRP78)83–90, albeit IFN-γ 
has been investigated most intensively. The ability of type II interferon for inducing the expression of immu-
noregulatory encountered genes, including IDO1, in MSCs from different sources was previously  reviewed91,92. 
Our quantitative RT-PCR experiments performed to elucidate possible effects of BiP on the expression levels of 
some immune-related genes, for the first time, indicated its ability for the induction of several innate and adap-
tive effector gene expressions in the hTERT-MSCs. A concentration of 10 µg/ml BiP can recapitulate, to some 
extent, the molecular profile of IFN-γ-treated cells at 72 h.
Based on the analyses performed in the present study, the increased immunomodulatory capacity of hTERT-
MSCs was in the same order as primary cultures of MSCs upon treatment with IFN-γ. Furthermore, the Western 
blot experiments confirmed the existence of the IDO1 protein in EVs from hTERT-MSCs-IFN-γ, but not for 
the untreated or poly(I:C)-treated cell-derived EVs. This is in line with a recent report that exosomes isolated 
from IFN-γ primed BM-MSCs were enriched with full-length IDO1 transcripts. Interestingly, exosomal transfer 
of the IDO1 transcripts toward PBMCs resulted in an increased expression of IDO1 in these recipient  cells39.
The importance of IDO1 among other soluble factors released to the conditioned media of primary cultures 
of MSCs is already  known93,94. In line with the interesting results obtained from treatment of hTERT-MSCs with 
IFN-γ, human IDO1, PTGS2, and TGF‑β1 genes were shortlisted for ectopic expression in these cells. These were 
recognized as soluble factors secreted by MSCs and are responsible for some parts of their functional  properties95.
Molecular analysis performed on the genetically modified hTERT-MSCs in this study revealed remark-
able overexpression of the transgenes with downstream functional consequences. Ectopic expression of IDO1, 
PTGS2, and TGF‑β1, individually or in combination, significantly increased the immunomodulatory properties of 
hTERT-MSCs as demonstrated by the lymphocyte inhibition assay. These antiproliferative effects against human 
PBMCs were more efficient in comparison to what was obtained by priming the cells with IFN-γ.
Many authors suggest that MSCs possess an intrinsic capacity for inducing innate and adaptive immune sys-
tem players to create a tolerogenic  environment96–101. Based on the molecular and functional analyses performed 
in the present study, this ability is also confirmed for hTERT-MSCs licensed by IFN-γ or genetically engineered 
cells to concurrently overexpress IDO1, PTGS2, and TGF‑β1 in the co-transduced cells.
The expression levels of different genes were investigated in the present study to compare the molecular profile 
of hTERT-MSCs following the application of priming/gene manipulation schedules. IDO1, IDO2, and TDO2 are 
three enzymes that are encountered in the tryptophan degradation pathway, among which IDO1 is the most stud-
ied one due to its unique properties. As IDO2 and TDO2 are also involved in regulating immune  responses102,103, 
we investigated their expression patterns in primed and/or modified cells to monitor their  modifications104,105. 
In the case of the IFN-γ (250 U/ml, 48 h)-primed cells, which were applied as the positive control during our 
experiments, concurrent overexpression of the main target genes was observed in the absence of IDO2 or TDO2 
with overlapping  functions106. Although IDO1 and its homolog IDO2 are encoded by linked genes, their immu-
noregulatory features seem to be completely different. Whereas IDO1 mediates T-cell responses in the benefit of 
anti-inflammation, IDO2 mediates B-cell responses towards a pro-inflammatory  phenotype107.
From the mechanistic point of view, IDO1-mediated immunoregulation is attributed to the establishment of 
a local tryptophan-deficient microenvironment, initiating a metabolic stress status that activates GCN2 kinase 
and mTOR pathways. Consequently, these events lead to T cell anergy. IDO1 also mediates the activation of 
regulatory T cells to create an in vivo immunomodulatory status.
IFITM and OAS families are classified as ISGs, which have prominent roles during the antiviral immune 
defense. The ISGs themselves are classified into antiviral effectors and regulators of type I IFN  signaling108. ISG15, 
2′–5′-oligoadenylate synthetase (OAS) is one of the most studied ISGs that is a ubiquitin-like protein. It is found 
in both intracellular and extracellular spaces as a free or covalently protein-conjugated  molecule109. ISG15 is 
a critical part of the antiviral defense mechanism in  mice110, whereas such a role is not confirmed in humans. 
However, ISG15 plays a role in anti-mycobacterial immunity in  humans111.
Different pathways are involved in cytokine signaling based on the regulation of the immune system, includ-
ing interferon-alpha/beta signaling, interferon-gamma signaling, interleukin-1 family signaling, interleukin-10 
signaling, and the antiviral mechanism by IFN-stimulated genes (ISG15 antiviral mechanism)112. DDX-58, an 
innate immune receptor, is involved in DDX-58/IFIH1-mediated induction of interferon-alpha/beta and anti-
viral mechanism triggered by IFN-stimulated genes. IFIH1 (MDA-5) is another innate immune receptor that 
plays a prominent role in mediating innate immune responses via recognition of RNA metabolites produced 
by RNase L (www. genec ards. org). IFIH1 expression leads to the activation of interferon cascade, whereas OAS2 
gene expression is induced by both type I and type II  interferons113. Upregulation of IDO1, IFIH1, and OAS2 
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was reported following infectious  diseases112. STING is a pattern recognition receptor whose alterations were 
investigated due to its role in autoimmune diseases and innate immune responses following the detection of 
cytoplasmic DNA (www. genec ards. org). Detailed molecular mechanisms encountered with STING functions 
during inflammation, infection, and cancer are fully described  previously114. HLA-DR expression as an MHC 
class II cell surface receptor was also investigated to compare the immunomodulatory status of the cells. In a study 
performed by Mao and coworkers, expression levels of Il‑6, Il‑10, Ccl2, Ccl5, TGF‑β, Nos‑2, TSG‑6, Mpges‑2, and 
Cox‑2 were investigated as genes with immunoregulatory functions in MSCs following  microencapsulation115. 
It was also demonstrated that IDO1, HGF, PD-L1, and IL-6 were induced following the secretion of IFN-γ by 
activated T-cells. These factors play a prominent role in recapitulating the proper microenvironment for MSCs 
to express their immunoregulatory  functions93.
It was also concluded that 104 peptides, including some proteins with anti-inflammatory functions such as 
Gal-1 and PD-L1116–121 were uniquely enriched in EV preparations from MSCs primed with IFN-γ. This study 
was the first experiment that confirmed the prominent role of IDO1 in mediating EVs’ therapeutic efficacy in vivo 
using a mouse model of experimental autoimmune encephalomyelitis (EAE)39.
Significant results were also observed for EVs extracted from the conditioned media of all genetically modi-
fied hTERT-MSCs in comparison to EVs from control or even primed cells with IFN-γ or poly(I:C). It is noted 
that IDO1 significantly improved the immunosuppressive features of cells, their conditioned media, and EV 
preparations in comparison to their equivalents from mock-transfected cells. In line with our findings, previ-
ous publications have demonstrated the improvement in immunomodulatory properties of different cell types 
following the ectopic expression of IDO1, which is widely accepted as one of the main playing factors in MSC 
 immunomodulation22,71,122,123. In the present study, we demonstrated the superior properties of EVs derived 
from hTERT-MSCs-IDO1 from different aspects to benefit their functional immunosuppressive properties.
This statistically significant difference in the functional properties of IDO1-derived cell-free products, could 
be attributed to the appropriate size of EVs, their higher stability, and proper biomechanical properties. The 
remarkable increase of IDO1 in the conditioned media of the hTERT-MSCs-IDO1 and its transfer/uptake by 
PBMCs could be considered as effective mechanisms facilitating the superior immunoregulatory properties of 
the cells. As revealed by qRT-PCR experiments the conditioned media of IDO1-transduced cells was enriched 
 (228-fold change) with IDO1 transcript in comparison to GFP controls. It was previously proposed that IDO1 can 
define a local immunosuppressed microenvironment via its catalytic activity and fine tuning of active immune 
cells’ balance. This includes mainly cytotoxic and regulatory T cells, B cells, and natural killer cells to benefit an 
immune-balanced  microenvironment124,125.
It is now vastly believed that EVs are instrumental in the packaging and delivery of the communicating 
molecules. Developing protocols for a generation of EVs with enriched master molecules would benefit many 
therapeutic programs as a substitute to direct cell therapy. Based on data from this study, we would suggest 
immortalized MSC-derived EVs enriched with IDO1 as an appropriate candidate in the modulation of immune-
related challenges in many scientific or even pre-clinical studies.
Materials and methods
Cell lines and primary cultures. Human immortalized adipose tissue-derived mesenchymal stem cells 
(hTERT-MSCs) were kindly provided by Prof. Steven A. Jonsen (University Medical Center of Göttingen, Ger-
many) and cultured in Dulbecco’s modified Eagle’s medium/Ham’s F-12 (DMEM/F12) medium (Gibco, Scot-
land). These cells were previously established from tissue samples of a 30-year-old female and fully characterized 
by Tatrai et al.126. Jurkat cells (Pasteur Institute, Tehran, Iran) were characterized using anti-human candidate 
antibodies (Supplementary Table S4). HEK293T cells and Jurkat cells were cultured in DMEM-high glucose 
and Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Scotland), respectively. During cell culture 
procedures, Fetal Bovine Serum (FBS) was applied as the nutritional supplement (10% V/V). Human peripheral 
blood mononuclear cells (PBMCs) were prepared as primary cultures based on the ethical guidelines of the 
National Institute for Medical Research Development, which are in accordance with the World Medical Asso-
ciation Declaration of Helsinki. All experimental protocols were approved by the Ethics Committee of NIMAD 
(ethics code: IRNIMADREC1396040). PBMCs were prepared freshly (in K3EDTA tubes) from healthy volun-
teers with written informed consent. PBMCs were characterized with single-color antibodies against CD45, 
CD3, and CD8 (Table S4).
Priming and genetic engineering approaches. Cell conditioning and viability test. HTERT-MSCs 
(10,000 cells/well) were treated with human recombinant interferon-gamma (250 U/ml and 500 U/ml; Type 
II, > 98% purity, RIFNG50, Invitrogen, USA), and polyinosinic: polycytidylic acid (10  µg/ml and 20  µg/ml; 
poly(I:C), P1530, Sigma-Aldrich, USA) for 24 h to 72 h. Furthermore, hTERT-MSCs were treated with 10 µg/ml 
(72 h) of human recombinant GRP78 (BiP) full-length protein (StressMarq, Biosciences, SPR-107). IFN-γ and 
poly(I:C) primed hTERT-MSCs were subjected to MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; Sigma-Aldrich, Germany, final concentration 500 µg/ml) assay to assess the viability of the cells.
Lentiviral gene transfer. Lentiviral vectors including pLenti-CMV-GFP-2A-Puro-Blank as control (LV590), 
and pLenti-CMV-GFP-2A-Puro containing either of the IDO1 (LV186089), PTGS2 (LV276675), and TGF‑β1 
(LV333458) insert sequences were purchased from ABM, USA. HEK293T cells were  transfected127 in the pres-
ence of dR8.91 and pMD2.G plasmids. Viral particles were enriched (80-folds) following centrifugation, fil-
tration, and ultracentrifugation (at 70,000g for 1 h, fixed-angle rotor type 50.2 Ti rotor, K-factor 69, Optima 
ultracentrifuge, Model L-90K, Beckman, USA) steps. Different viral constructs (IDO1, PTGS2, and TGF‑β1) 
were introduced to the hTERT-MSCs individually or in combination with each other in the co-transduced 
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group. Non-transduced cells and cells transduced with the blank vector (hTERT-MSCs-GFP) were considered 
as controls throughout the experiments. HTERT-MSCs successfully transduced with the target constructs were 
selected based on their acquired resistance to puromycin (1 µg/ml to 2 µg/ml; 48 h, BioBasic, Canada) and were 
applied for downstream applications on days 5 to 7 post-transduction.
Immunocytochemistry and Western blot analyses. Immunocytochemistry (ICC) analysis was per-
formed using 25,000 cells/well in 24 well plates (Sarstädt, Germany). Fixation (4% PFA, 20 min), washing (1X 
PBS), permeabilization (0.25% Triton X-100, 5 min without shaking), blocking (3% BSA, 0.25% Triton X-100, 
normal donkey serum in 1X PBS), and staining steps were performed 72 h post modifications, except for the 
negative controls. The cell nuclei were also stained with the fluorescent dye DAPI (Applichem, USA, Cat. No. 
A1001.0100). To do Western blot experiments against IDO1, PTGS2, and TGF-β1 (Supplementary Table S4), 
we prepared cell lysis by RIPA buffer (Cell Signaling Technology, USA) and PMSF (Cell Signaling Technology, 
USA), based on the instructions provided by the manufacturers.
Differentiation capacity assay. hTERT-MSCs were subjected to osteogenic differentiation in their nor-
mal state or following concurrent transduction with all investigated viral particles including IDO1, PTGS2 and 
TGF‑β1 in the hTERT-MSCs-co-trans group. IFN-γ (250 U/ml) and poly(I:C) (20 µg/ml) were constantly pre-
sent in the medium in case of differentiation induction procedure for primed cells. In order to induce osteogenic 
differentiation, β-glycerol phosphate disodium salt hydrate (Sigma-Aldrich, G9422-100, 100x), ascorbic acid 
(Sigma-Aldrich, 49752, 1000x) and dexamethasone (1000x) (dissolved in  ddH2O) stock solutions were added to 
the complete the culture medium with final concentrations of 10 mM (10 µl/ml), 0.5 mM (1 µl/ml), and 0.1 µM 
(1 µl/ml), respectively. The medium exchange was performed every 48 h for 3 weeks before staining with alizarin 
red S.
Molecular studies. Gene expression analyses (IDO1, IDO2, TDO2, PTGS2, and TGF‑β1) were performed 
on cDNA samples prepared from hTERT-MSCs treated with different concentrations of IFN-γ (250 U/ml, 500 
U/ml) and poly(I:C) (10, 20 µg/ml) for 24 to 72 h. The expression levels of a set of immune-encountered genes 
were investigated for IFN-γ (250 U/ml, 48 h) and poly(I:C)(20 µg/ml, 48 h) treated cells, in addition to the cells 
primed with BiP (10 µg/ml, 72 h). Moreover, the hTERT-MSCs, which were transduced with different viral par-
ticles, including the IDO1, PTGS2, and TGF‑β1 individually or in combination, were applied for gene expression 
analyses on day 7 post-infection. To compare different treatments, we did gene expression analysis for all the 
genes described in the Supplementary Table S5 in case of the primed or genetically engineered cells, but only 
genes with significant expression modifications are presented. TRIzol reagent (Ambion, USA) was applied for 
total RNA extraction. The RNA integrity and quantity were checked and measured by electrophoresis on agarose 
gel (1%) and using the Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, USA), respectively. 
One microgram of the DNase I-treated RNA was then applied for cDNA synthesis (all from Thermo Fisher 
Scientific, USA) in all cases. Relative gene expression analyses were performed using 2 × real-time PCR Master 
Mix Green-No Rox (Ampliqon, Denmark; CFX-96 Thermocycler, Bio-Rad, USA). Data analysis was performed 
by CFX Manager Software (version 1.6, Informer Technologies, Inc) and GraphPad Prism version 6.00 (Graph-
Pad Software, La Jolla California USA, www. graph pad. com). Primer sequences (Supplementary Table S5) were 
selected from previously published articles or otherwise designed by AlleleID 6.0 (Premier Biosoft, Palo Alto, 
CA, USA, http:// www. premi erbio soft. com).
EVs enrichment and characterization experiments. EVs isolation and purification. Culture media 
of hTERT-MSCs (T175 flasks; seeding density of 1 million cells/flask) were administered to enrich EVs fol-
lowing priming or transduction of the cells. Cells were cultured in the presence of exosome-depleted serum 
(one-shot fetal bovine serum, exosome depleted, A2720803, Thermo Fisher Scientific, USA) for two rounds 
of 72 h. It was followed by the pre-clearing steps (centrifugation at 400g for 6 min, 1500g for 30 min at 4 °C; 
syringe filtration with 0.45 µm and 0.22 µm filters), which were performed to remove dead cells, cell debris, 
and intact  organelles128. The ultracentrifugation method was applied for the enrichment of EVs (70,000g at 
4 °C for 1 h, fixed-angle rotor type 50.2 Ti rotor, K-factor 69, Optima ultracentrifuge, Model L-90K, Beckman, 
USA)129. Supernatants from the ultracentrifugation were collected in clean tubes, and the remained particles 
were enriched by the PEG-precipitation  method130. Besides, EV isolation was also performed by the commercial 
Exo-spin Kit (EX01, CellGS). The Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, USA) was then ap-
plied to measure the total protein content of EV preparations. All relevant data of our experiments, which were 
in accordance with the ISEV  guidelines131,132, were submitted to the EV-TRACK knowledgebase (EV-TRACK 
ID: 190081)133.
Nanoparticle tracking analysis. Size distribution and the number of particles/ml in each sample (1:100) were 
measured by a Nanosight NS300 (Malvern Instrument, Malvern, UK) equipped with a 405 nm laser. A 30 s video 
was automatically recorded for each sample (detection threshold 10 Multi). The processed data were automati-
cally obtained as a PDF file (Nano Tracking Analysis (NTA) version 2.3).
Dynamic light scattering and zeta potential analyses. Fresh EV preparations (diluted 1–20 in PBS) were loaded 
onto the Particle Size Analyzer Cordouan (Vasco3, France). Zeta potential analysis was performed for all the EV 
samples, diluted in deionized water (1–80) (Zeta Potential, Zeta Compact, CAD, France).
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Atomic force microscopy (AFM). To perform AFM, we loaded 1 µl of diluted EV preparations (1:200) onto the 
freshly cleaved mica and air-dried at room temperature. Imaging was performed in non-contact mode with sili-
con probe (Tip thickness 10 nm, scan size range 3 µm × 3 µm) covered with aluminum with a scan rate of 3 lines 
per second. Force spectroscopy was also performed with scan size ranges from 0 to 100 nm in both directions. 4 
points with 5 repeats were investigated per  sample134,135.
Western blot. Western blot analysis was performed to verify the expression of widely accepted exosomal mark-
ers, including CD63 (Biorbyt, orb11317; 1:500) and TSG101 (Genetex, GTX70255; 1:500). Goat anti-rabbit IgG-
HRP (Santa Cruz, sc-2004) and goat anti-mouse IgG-HRP (Santacruz, SC-2005) were applied as secondary 
antibodies, respectively. Primary mouse monoclonal IgG1 anti-beta Actin antibody [AC-15] (abcam, AB6276) 
was used as an internal control. EVs (25 µg) were directly diluted 1 to 4 in sample buffer and were applied for 
western blot experiments following 6-min denaturation at 95 °C. SuperSignal West Femto Kit, Thermo Fisher 
Scientific, USA) was applied for signal detection.
Transmission electron microscopy. EV samples were negatively stained with 2% uranyl acetate and applied for 
microscopic characterization following Rikkert’s protocol with minor  modifications136. A similar procedure was 
applied for the PEG-concentrated ultracentrifuge supernatants, except that samples were diluted (fivefold) in 
deionized water.
Functional analysis. Lymphocyte inhibition (Orangu) assay. HTERT-MSCs were co-cultured (6-well for-
mat) with human PBMCs in RPMI 1640 medium. 72 h later, cell viability was calculated for suspension cells 
using an Orangu colorimetric assay (Orangu dye, cell counting solution, OR01-500, CellGS), and ODs were read 
at 450 nm. In addition to MSCs, conditioned medium, isolated EVs, as well as intact and concentrated ultracen-
trifuge supernatants from different groups, were applied for functional analyses against hPBMCs and/or Jurkat 
cells in the presence of PHA (3 µg/ml). Functional analyses were performed in 24-well plates for all the cell-free 
products in the presence of 10% exosome-depleted FBS in the media.
Cell proliferation analysis by flow cytometry. CellTrace CFSE Cell Proliferation Kit (Invitrogen, Cat No. 
C34554) was used to investigate cell proliferation along with different generations following co-culture experi-
ments. PBMCs/Jurkat cells were stained with 10 µM CFSE according to the manufacturer’s instructions and were 
applied to flow cytometric analysis at different time periods (PBMCs/Jurkat: MSCs ratio 10:1). Propidium iodide 
(PI, Sigma-Aldrich) staining was also applied to remove dead cells  (PI+ cells) from the analysis. Functional 
analyses were performed in the presence of exosome-depleted FBS. In the case of EVs, freshly prepared hPB-
MCs (5 ×  105 cells/well) stained with CFSE (10 µM), were co-cultured with EVs (50 µg/well) enriched from the 
conditioned media of virally transduced or IFN-γ-primed cells for 5 days (Exosome Isolation Kit, CellGS, UK).
Statistical analyses. We statistically compared the investigated variables, including cell viability and gene 
expression levels among different treatment schedules, using a one-way analysis of variance (ANOVA) and mul-
tiple comparisons. Each variable is reported as the mean of three independent experiments ± standard error 
of the mean (SEM). Differences between groups were considered statistically significant at a p value of < 0.05. 
Statistical analyses were performed with GraphPad Prism version 6.00.
Data availability
The data used to support the findings of this study are included in the main article or in the Supplementary 
information files. In case of each analysis, instruments, technical details, sample preparation steps, number of 
biological or technical repeats, and special software applied for data analysis are also reported. Commercial 
lentiviral plasmids, reagents and chemicals, cat numbers and providers are mentioned in the manuscript. All 
relevant data of our experiments were submitted to the EV-TRACK knowledgebase. You may access and check 
the submission via the following URL: http:// evtra ck. org/ review. php. Please use the EV TRACK ID (EV 190081) 
and the last name of the first author (Haghighitalab) to access our submission. Data not shown were submitted 
as Supplementary information (Supplementary figures for reviewers). More detailed information, including 
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raw data will be available from the corresponding author upon reasonable request.
Received: 30 September 2020; Accepted: 25 March 2021
References
 1. Najar, M. et al. Mesenchymal stromal cell-based therapy: New perspectives and challenges. J. Clin. Med. 8, 626 (2019).
 2. Vasanthan, J. et al. Role of human mesenchymal stem cells in regenerative therapy. Cells 10, 54 (2020).
 3. Shammaa, R., El-Kadiry, A. E., Abusarah, J. & Rafei, M. Mesenchymal stem cells beyond regenerative medicine. Front. Cell Dev. 
Biol. 8, 72 (2020).
 4. Brooke, G., Tong, H., Levesque, J. P. & Atkinson, K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells 
derived from human bone marrow and placenta. Stem Cells Dev. 17, 929–940 (2008).
 5. Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. 
Lancet 363, 1439–1441 (2004).
 6. Li, H. et al. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal 
acute graft-versus-host disease. Stem Cells. 26, 2531–2541 (2008).
16
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7825  | https://doi.org/10.1038/s41598-021-87153-7
www.nature.com/scientificreports/
 7. Choi, J. R., Yong, K. W. & Nam, H. Y. Current status and perspectives of human mesenchymal stem cell therapy. Stem Cells Int. 
2019, 4762634 (2019).
 8. Lukomska, B. et al. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019, 9628536 (2019).
 9. Nikitina, V. et al. Clonal chromosomal and genomic instability during human multipotent mesenchymal stromal cells long-term 
culture. PLoS ONE 13, e0192445 (2018).
 10. Gomez-Salazar, M. et al. Five decades later, are mesenchymal stem cells still relevant?. Front. Bioeng. Biotechnol. 8, 148 (2020).
 11. Harrell, C. R. et al. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. 
Cells 8, 467 (2019).
 12. Akasaki, Y. et al. Induction of a  CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 
173, 4352–4359 (2004).
 13. Beyth, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. 
Blood 105, 2214–2219 (2005).
 14. Ge, W. et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with 
indoleamine 2,3-dioxygenase expression. Transplantation 90, 1312–1320 (2010).
 15. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to 
their cognate peptide. Blood 101, 3722–3729 (2003).
 16. Puissant, B. et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: Comparison with bone marrow 
mesenchymal stem cells. Br. J. Haematol. 129, 118–129 (2005).
 17. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. 
Cell Stem Cell 2, 141–150 (2008).
 18. Sato, K. et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109, 
228–234 (2007).
 19. Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C. & Guinan, E. C. Suppression of allogeneic T-cell proliferation by human 
marrow stromal cells: Implications in transplantation. Transplantation 75, 389–397 (2003).
 20. Wu, R. et al. Enhanced alleviation of a GVHD by TGF-β1-modified mesenchymal stem cells in mice through shifting MΦ into 
M2 phenotype and promoting the differentiation of Treg cells. Cell Mol. Med. 24, 1684–1699 (2020).
 21. Yañez, R. et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the 
control of the graft-versus-host disease. Stem Cells. 24, 2582–2591 (2006).
 22. Meireson, A., Devos, M. & Brochez, L. IDO expression in cancer: Different compartment, different functionality?. Front. Immu‑
nol. 11, 531491 (2020).
 23. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191–1193 (1998).
 24. Silva, N. M. et al. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo 
infection with Toxoplasma gondii: Induction by endogenous g interferon and requirement of interferon regulatory factor 1. Infect. 
Immun. 70, 859–868 (2002).
 25. Brown, R. R. et al. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. 
Exp. Med. Biol. 294, 425–435 (1991).
 26. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor draining lymph nodes. 
J. Clin. Investig. 114, 280–290 (2004).
 27. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 
2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
 28. von Bahr, L. et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraft-
ment and no ectopic tissue formation. Stem Cells. 30, 1575–1578 (2012).
 29. Kean, T. J., Lin, P., Caplan, A. I. & Dennis, J. E. MSCs: Delivery routes and engraftment, cell-targeting strategies, and immune 
modulation. Stem Cells Int. 2013, 732742 (2013).
 30. Li, Y., Qiu, W., Zhang, L., Fung, J. & Lin, F. Painting factor H onto mesenchymal stem cells protects the cells from complement- 
and neutrophil-mediated damage. Biomaterials 102, 209–219 (2016).
 31. Hartjes, T. A., Mytnyk, S., Jenster, G. W., van Steijn, V. & van Royen, M. E. Extracellular vesicle quantification and characteriza-
tion: Common methods and emerging approaches. Bioengineering (Basel) 6, 7 (2019).
 32. Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 13, 392–402 
(2013).
 33. De Miguel, M. P. et al. Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr. Mol. Med. 
12, 574–591 (2012).
 34. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular 
vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).
 35. Gould, S. J. & Raposo, G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J. Extracell Vesicles. 
https:// doi. org/ 10. 3402/ jev. v2i0. 20389 (2013).
 36. Mathieu, M., Martin-Jaular, L., Lavieu, G. & Théry, C. Specificities of secretion and uptake of exosomes and other extracellular 
vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019).
 37. Yáñez-Mó, M. et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles. 4, 27066 
(2015).
 38. Basu, J. & Ludlow, J. W. Exosomes for repair, regeneration and rejuvenation. Expert Opin. Biol. Ther. 16, 489–506 (2016).
 39. Riazifar, M. et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano 
13, 6670–6688 (2019).
 40. Jafari, D. et al. Designer exosomes: A new platform for biotechnology therapeutics. BioDrugs 34, 567–586 (2020).
 41. Villa, F., Quarto, R. & Tasso, R. Extracellular vesicles as natural, safe and efficient drug delivery systems. Pharmaceutics. 11, 557 
(2019).
 42. Park, K. S., Bandeira, E., Shelke, G. V., Lässer, C. & Lötvall, J. Enhancement of therapeutic potential of mesenchymal stem cell-
derived extracellular vesicles. Stem Cell Res. Ther. 10, 288 (2019).
 43. Suh, J. H., Joo, H. S., Hong, E. B., Lee, H. J. & Lee, J. M. Therapeutic application of exosomes in inflammatory diseases. Int. J. 
Mol. Sci. 22, 1144 (2021).
 44. Baldari, S. et al. Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. 
Int. J. Mol. Sci. 18, 2087 (2017).
 45. Seo, Y., Shin, T. H. & Kim, H. S. Current strategies to enhance adipose stem cell function: An update. Int. J. Mol. Sci. 20, 3827 
(2019).
 46. Baglio, S. R. et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA 
and tRNA species. Stem Cell Res. Ther. 6, 127 (2015).
 47. Rani, S., Ryan, A. E., Griffin, M. D. & Ritter, T. Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic 
applications. Mol. Ther. 23, 812–823 (2015).
 48. Liu, Y. & Holmes, C. Tissue regeneration capacity of extracellular vesicles isolated from bone marrow-derived and adipose-
derived mesenchymal stromal/stem cells. Front. Cell Dev. Biol. 9, 648098 (2021).
17
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7825  | https://doi.org/10.1038/s41598-021-87153-7
www.nature.com/scientificreports/
 49. Ansari, A. M. et al. Cellular GFP toxicity and immunogenicity: Potential confounders in in vivo cell tracking experiments. Stem 
Cell Rev. Rep. 12, 553–559 (2016).
 50. Mastrolia, I. et al. Challenges in clinical development of mesenchymal stromal/stem cells: Concise review. Stem Cells Transl. 
Med. 8, 1135–1148 (2019).
 51. Wiest, E. F. & Zubair, A. C. Challenges of manufacturing mesenchymal stromal cell-derived extracellular vesicles in regenerative 
medicine. Cytotherapy 22, 606–612 (2020).
 52. Zhou, Y., Yamamoto, Y., Xiao, Z. & Ochiya, T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated 
via paracrine activity. J. Clin. Med. 8, 1025 (2019).
 53. Collino, F. et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected 
pattern of miRNAs. PLoS ONE 5, e11803 (2010).
 54. Hass, R. & Otte, A. Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Com‑
mun. Signal. 10, 26 (2012).
 55. Xin, H. et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes 
to neurite out growth. Stem Cells. 30, 1556–1564 (2012).
 56. Lee, J. K. et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by downregulating VEGF expression in 
breast cancer cells. PLoS ONE 8, e84256 (2013).
 57. Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Investig. 
123, 1542–1555 (2013).
 58. Wang, J. et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. 
Blood 124, 555–566 (2014).
 59. Kfoury, Y. & Scadden, D. T. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell 16, 239–253 (2015).
 60. Ratajczak, M. Z., & Ratajczak, J. Innate immunity communicates using the language of extracellular microvesicles. Stem Cell 
Rev. Rep. https:// doi. org/ 10. 1007/ s12015- 021- 10138-6 (2021).
 61. Ha, D., Yang, N. & Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current 
perspectives and future challenges. Acta Pharm. Sin. B. 6, 287–296 (2016).
 62. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).
 63. Zhang, B. et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 23, 1233–1244 (2014).
 64. Liu, C. & Su, C. Design strategies and application progress of therapeutic exosomes. Theranostics. 9, 1015–1028 (2019).
 65. Domenis, R. et al. Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-
derived exosomes. Sci. Rep. 8, 13325 (2018).
 66. Harting, M. T. et al. Inflammation-stimulated mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation. 
Stem Cells (Dayton, Ohio). 36, 79–90 (2018).
 67. Joo, H. S., Suh, J. H., Lee, H. J., Bang, E. S. & Lee, J. M. Current knowledge and future perspectives on mesenchymal stem cell-
derived exosomes as a new therapeutic agent. Int. J. Mol. Sci. 21, 727 (2020).
 68. Park, J. S., Suryaprakash, S., Lao, Y. H. & Leong, K. W. Engineering mesenchymal stem cells for regenerative medicine and drug 
delivery. Methods (San Diego, Calif.). 84, 3–16 (2015).
 69. Varderidou-Minasian, S. & Lorenowicz, M. J. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: 
Challenges and opportunities. Theranostics. 10, 5979–5997 (2020).
 70. Heo, J. S., Choi, Y., Kim, H. S. & Kim, H. O. Comparison of molecular profiles of human mesenchymal stem cells derived from 
bone marrow, umbilical cord blood, placenta and adipose tissue. Int. J. Mol. Med. 37, 115–125 (2016).
 71. Li, C. Y. et al. Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free 
conditions for cell therapy. Stem Cell Res. Ther. 6, 55 (2015).
 72. Melief, S. M., Zwaginga, J. J., Fibbe, W. E. & Roelofs, H. Adipose tissue-derived multipotent stromal cells have a higher immu-
nomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl. Med. 2, 455–463 (2013).
 73. Waldner, M. et al. Characteristics and immunomodulating functions of adipose-derived and bone marrow-derived mesenchymal 
stem cells across defined human leukocyte antigen barriers. Front. Immunol. 9, 1642 (2018).
 74. Wang, Z. G. et al. Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and 
umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 11, 511 (2020).
 75. Twine, N. A. et al. Molecular phenotyping of telomerized human bone marrow skeletal stem cells reveals a genetic program of 
enhanced proliferation and maintenance of differentiation responses. JBMR Plus. 2, 257–267 (2018).
 76. Chen, T. S. et al. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization 
of human ESC-derived MSCs. J. Transl. Med. 9, 47 (2011).
 77. Lai, R. C. et al. Isolation and characterization of exosome from human embryonic stem cell-derived C-Myc-immortalized 
mesenchymal stem cells. Methods Mol. Biol. 1416, 477–494 (2016).
 78. Rohde, E., Pachler, K. & Gimona, M. Manufacturing and characterization of extracellular vesicles from umbilical cord-derived 
mesenchymal stromal cells for clinical testing. Cytotherapy 21, 581–592 (2019).
 79. Krampera, M. et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem 
cells. Stem Cells. 24, 386–398 (2006).
 80. Fuenzalida, P. et al. Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal 
stromal cells in a dextran sulfate sodium-induced colitis model. Cytotherapy 18, 630–641 (2016).
 81. Najar, M., Krayem, M., Meuleman, N., Bron, D. & Lagneaux, L. Mesenchymal stromal cells and Toll-like receptor priming: A 
critical review. Immune Netw. 17, 89–102 (2017).
 82. Raicevic, G. et al. Comparison and immunobiological characterization of retinoic acid inducible gene-I-like receptor expression 
in mesenchymal stromal cells. Sci. Rep. 7, 2896 (2017).
 83. Corrigall, V. M. et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis 
and prevents the induction of experimental arthritis. J. Immunol. 166, 1492–1498 (2001).
 84. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB 
by Toll-like receptor 3. Nature 413, 732–738 (2001).
 85. Bardel, E. et al. Intradermal immunisation using the TLR3-ligand poly(I:C) as adjuvant induces mucosal antibody responses 
and protects against genital HSV-2 infection. NPJ Vaccines. 1, 16010 (2016).
 86. Brownlie, R. J. et al. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regula-
tory T cells: A novel function for an ancient protein. Arthritis Rheum. 54, 854–863 (2006).
 87. Klincumhom, N., Chaikeawkaew, D., Adulheem, S., Pavasant, P. Activation of TLR3 enhance stemness and immunomodulatory 
properties of periodontal ligament stem cells (PDLSCs). In Interface Oral Health Science 2016. (eds. Sasaki, K., Suzuki, O. & 
Takahashi, N.) (Springer, 2017). https://doi.org/https:// doi. org/ 10. 1007/ 978- 981- 10- 1560-1_ 17.
 88. Ryu, D. B., Lim, J. Y., Lee, S. E., Park, G. & Min, C. K. Induction of Indoleamine 2,3-dioxygenase by pre-treatment with poly(I:C) 
may enhance the efficacy of MSC treatment in DSS-induced colitis. Immune Netw. 16, 358–365 (2016).
 89. Salem, M. L. et al. The TLR3 agonist poly(I:C) targets  CD8+ T cells and augments their antigen-specific responses upon their 
adoptive transfer into naive recipient mice. Vaccine. 27, 549–557 (2009).
 90. Wang, B. et al. Toll-like receptor-3 ligation-induced indoleamine 2,3-dioxygenase expression in human trophoblasts. Endocrinol‑
ogy 152, 4984–4992 (2011).
18
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7825  | https://doi.org/10.1038/s41598-021-87153-7
www.nature.com/scientificreports/
 91. Carvalho, A., Sousa, M., Alencar-Silva, T., Carvalho, J. L. & Saldanha-Araujo, F. Mesenchymal stem cells immunomodulation: 
The road to IFN-γ licensing and the path ahead. Cytokine Growth Factor Rev. 47, 32–42 (2019).
 92. Li, H. et al. Immunomodulatory functions of mesenchymal stem cells in tissue engineering. Stem Cells Int. 2019, 9671206 (2019).
 93. Davies, L. C., Heldring, N., Kadri, N. & Le Blanc, K. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates 
T cell mediated immunosuppression. Stem Cells. 35, 766–776 (2017).
 94. Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated 
tryptophan degradation. Blood 103, 4619–4621 (2004).
 95. Podestà, M. A., Remuzzi, G. & Casiraghi, F. Mesenchymal stromal cells for transplant tolerance. Front. Immunol. 10, 1287 (2019).
 96. Le Blanc, K. & Mougiakakos, D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12, 
383–396 (2012).
 97. English, K. & Mahon, B. P. Allogeneic mesenchymal stem cells: Agents of immune modulation. J. Cell Biochem. 112, 1963–1968 
(2011).
 98. Gallagher, D. et al. MSC modulate peripheral stress-induced innate immune activation indirectly limiting the emergence of 
neuroinflammation and depressive/anxiety-like behaviors. Biol. Psychiatry. 86, 712–724 (2019).
 99. Gao, F. et al. Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis. 7, e2062 
(2016).
 100. Ho, M. S. H., Mei, S. H. J. & Stewart, D. J. The immunomodulatory and therapeutic effects of mesenchymal stromal cells for 
acute lung injury and sepsis. J. Cell Physiol. 230, 2606–2617 (2015).
 101. Najar, M. et al. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy 18, 
160–171 (2016).
 102. Lovelace, M. D. et al. Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis. 
Front. Immunol. 7, 246 (2016).
 103. Metz, R. et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int. 
Immunol. 31, 181–182 (2019).
 104. Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B. & Muller, A. J. Discovery of IDO1 inhibitors: From bench to bedside. 
Cancer Res. 77, 6795–6811 (2017).
 105. Prendergast, G. C., Metz, R., Muller, A. J., Merlo, L. M. F. & Mandik-Nayak, L. IDO2 in immunomodulation and autoimmune 
disease. Front. Immunol. 5, 585 (2014).
 106. Günther, J., Fallarino, F., Fuchs, D. & Wirthgen, E. Editorial: Immunomodulatory roles of tryptophan metabolites in inflamma-
tion and cancer. Front. Immunol. 11, 1497 (2020).
 107. Merlo, L. et al. Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Front. Immunol. 11, 1861 
(2020).
 108. Raftery, N. & Stevenson, N. J. Advances in antiviral immune defence: Revealing the importance of the IFN JAK/STAT pathway. 
Cell Mol. Life Sci. 74, 2525–2535 (2017).
 109. Zhao, C., Collins, M. N., Hsiang, T. Y. & Krug, R. M. Interferon-induced ISG15 pathway: An ongoing virus-host battle. Trends 
Microbiol. 21, 181–186 (2013).
 110. Lenschow, D. J. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis 
viruses. Proc. Natl. Acad. Sci. U. S. A. 104, 1371–1376 (2007).
 111. Bogunovic, D. et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 
337, 1684–1688 (2012).
 112. Pfaff, F. et al. Proteogenomics uncovers critical elements of host response in bovine soft palate epithelial cells following in vitro 
infection with Foot-And-Mouth Disease virus. Viruses 11, E53 (2019).
 113. Sanda, C. et al. Differential gene induction by type I and type II interferons and their combination. J. Interferon Cytokine Res. 
26, 462–472 (2006).
 114. Barber, G. N. STING: Infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).
 115. Mao, A. S. et al. Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation. 
Proc. Natl. Acad. Sci. U. S. A. 116, 15392–15397 (2019).
 116. Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 
382–386 (2018).
 117. Chen, W. et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol. Res. 64, 831–840 (2016).
 118. Del Fattore, A. et al. Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell 
Transplant. 24, 2615–2627 (2015).
 119. Gonçalves, F. D. C. et al. Membrane particles generated from mesenchymal stromal cells modulate immune responses by selec-
tive targeting of pro-inflammatory monocytes. Sci. Rep. 7, 12100 (2017).
 120. Kilpinen, L. et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney 
injury, a feature that is lost after inflammatory conditioning. J. Extracell. Vesicles. 10, 2 (2013).
 121. Mokarizadeh, A. et al. Microvesicles derived from mesenchymal stem cells: Potent organelles for induction of tolerogenic signal-
ing. Immunol. Lett. 147, 47–54 (2012).
 122. Ghahary, A. et al. Expression of indoleamine 2,3-dioxygenase in dermal fibroblast functions as a local immunosuppressive 
factor. J. Investig Dermatol. 122, 953–964 (2004).
 123. Lee, Y. K. et al. Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3 dioxygenase 
1 (IDO1) by IDO2. Exp. Mol. Med. 46, e121 (2014).
 124. Mellor, A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. 338, 20–24 (2005).
 125. Wu, H., Gong, J. & Liu, Y. Indoleamine 2, 3-dioxygenase regulation of immune response (Review). Mol. Med. Rep. 17, 4867–4873 
(2018).
 126. Tátrai, P. et al. Combined introduction of Bmi-1 and hTERT immortalizes human adipose tissue-derived stromal cells with low 
risk of transformation. Biochem. Biophys. Res. Commun. 422, 28–35 (2012).
 127. Barde, I., Salmon, P. & Trono, D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. 53, 4–21 (2010).
 128. Zhang, Y., Liu, Y., Liu, H. & Tang, W. H. Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci. 9, 19 (2019).
 129. Chiang, C. Y. & Chen, C. Toward characterizing extracellular vesicles at a single-particle level. J. Biomed. Sci. 26, 9 (2019).
 130. Ludwig, A. K. et al. Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches 
extracellular vesicles from tissue culture supernatants in small and large scales. J. Extracell. Vesicles. 7, 1528109 (2018).
 131. Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the Inter-
national Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles. 7, 1535750 (2018).
 132. Witwer, K. W. et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. 
J. Extracell. Vesicles. 8, 1609206 (2019).
 133. Van Deun, J. et al. EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research. Nat. Methods. 
14, 228–232 (2017).
 134. Sharma, S., LeClaire, M. & Gimzewski, J. K. Ascent of atomic force microscopy as a nanoanalytical tool for exosomes and other 
extracellular vesicles. Nanotechnology 29, 132001 (2018).
19
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7825  | https://doi.org/10.1038/s41598-021-87153-7
www.nature.com/scientificreports/
 135. Ridolfi, A. et al. AFM-based high-throughput nanomechanical screening of single extracellular vesicles. Anal. Chem. 92, 10274–
10282 (2020).
 136. Rikkert, L. G., Nieuwland, R., Terstappen, L. & Coumans, F. Quality of extracellular vesicle images by transmission electron 
microscopy is operator and protocol dependent. J. Extracell. Vesicles. 8, 1555419 (2019).
Acknowledgements
This study was supported by the National Institute for Medical Research Development (NIMAD, Grant number 
957797) of Iran and Ferdowsi University of Mashhad (Grant number 41827). We would like to thank Moein 
Farshchian, Saeide Nakhaei-Rad, Mahboubeh Kazemi-Noughabi, Halimeh Hasanzadeh, Xuan Zheng and Fate-
meh Khakrah for their close scientific and technical support. The experiments were performed in the Depart-
ment of Biology and Central laboratory of the Ferdowsi University of Mashhad, the Department of Neurology 
of the University Medicine of Göttingen, and the Max Planck Institute for Biophysical Chemistry Göttingen.
Author contributions
All authors have given approval to the final version of the manuscript. A.H. performed the research, data acquisi-
tion and analysis, and wrote the manuscript. M.M.M. supervised the research project, performed data valida-
tion, edited the manuscript and contributed significantly to the project concept. A.A. and S.M. provided clinical 
resources setting. H.R.B. was involved in medical sample collection. A.R.B. and T.R.D. contributed to the project 
with conceptualization, supervision, and editing the manuscript. A.R.B., T.R.D. and M.M.M. were involved in 
funding acquisition.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 87153-7.
Correspondence and requests for materials should be addressed to A.R.B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
